Kelly Evans, DO
Internal Medicine · Manchester, KYNPI 1124107693
Payments from drug & device makers
Across 49 payments — averaging $17.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$134
- AbbVie$99
- Pfizer$92
- Novartis$72
- Otsuka America Pharmaceutical, Inc.$49
- Novo Nordisk$44
- plus $365 from 16 others
What the payments were for
- Food & beverage$83297%
- Education$223%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 8 | $134 |
| AbbVie(2 entities) | 3 | $99 |
| Pfizer | 6 | $92 |
| Novartis | 4 | $72 |
| Otsuka America Pharmaceutical, Inc. | 3 | $49 |
| Novo Nordisk | 3 | $44 |
| VBI Vaccine (delaware) Inc. | 3 | $37 |
| Amgen | 2 | $32 |
| Axsome Therapeutics, Inc. | 1 | $30 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| Genentech USA, Inc. | 2 | $28 |
| Medtronic | 1 | $25 |
| AstraZeneca | 2 | $23 |
| Mylan Specialty L.p. | 1 | $23 |
| Collegium Pharmaceutical, Inc. | 1 | $23 |
| Exact Sciences | 1 | $21 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $21 |
| Phadia US Inc. | 1 | $16 |
| Hologic Sales And Service, LLC | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| Astellas Pharma US Inc | 1 | $14 |
How this compares
$854 in reported general payments places this provider in the 60th percentile of 1,284 internal medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TradjentaLinagliptin | 219 | $63,212 |
| EliquisApixaban | 273 | $56,190 |
| OzempicSemaglutide | 35 | $41,136 |
| FarxigaDapagliflozin Propanediol | 92 | $38,909 |
| LinzessLinaclotide | 42 | $35,735 |
| RexultiBrexpiprazole | 25 | $30,792 |
| JardianceEmpagliflozin | 66 | $25,078 |
| TrulicityDulaglutide | 16 | $24,075 |
| XifaxanRifaximin | 13 | $20,979 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 26 | $16,476 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $14,039 |
| EntrestoSacubitril/Valsartan | 34 | $13,427 |
| RestasisCyclosporine | 17 | $11,161 |
| NuedextaDextromethorphan Hbr/Quinidine | 13 | $9,560 |
| ErtapenemErtapenem Sodium | 15 | $7,994 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $92 | $56,190273 claims |
| AbbVieLinzess, Restasis | $99 | $46,89659 claims |
| Novo NordiskOzempic | $44 | $41,13635 claims |
| AstraZenecaFarxiga | $23 | $38,90992 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $49 | $30,79225 claims |
| Lilly USA, LLCTrulicity | $14 | $24,07516 claims |
| NovartisEntresto | $72 | $13,42734 claims |
| MerckJanuvia | $134 | $6,55511 claims |
| Astellas Pharma US IncMyrbetriq | $14 | $4,39315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,284 internal medicine providers in Kentucky.
Other internal medicine in Manchester
- Mark AdamsLondon$15.4M
- Matthew WenkerErlanger$12.8M
- Jason ChesneyLouisville$6.3M
- Neil FarrisLexington$3M
- David JohnsonOwensboro$787K
- Hollis ClarkMurray$780K
- Fares KhaterWhitesburg$412K
- Christopher PhillipsPaducah$315K
- Cynthia Bowman-StroudPaducah$234K
- Bernard BuchananOwensboro$224K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.